ArticleVox sanguinis2019
The prevalence of human T-lymphotropic virus type 1 & 2 (HTLV-1/2) in South African blood donors.
Article in Vox sanguinis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- High prevalence of human T-cell leukemia virus type-1b genotype among blood donors in Gabon, Central Africa.Transfusion · 2020Trial
- High prevalence of HTLV-1 among blood donors in southeastern Gabon (Central Africa): a major challenge for transfusion safety in a semi-rural area.Microbiology spectrum · 2026Article
- Strengthening awareness and response to HTLV-1 infection in Africa: A neglected threat to blood safety and public health.HemaSphere · 2025Article
- Clinical and molecular evidences of HTLV-1 infection in inpatients diagnosed with diseases previously described as associated to this infection: A case series in Gabon, Central Africa.PLoS neglected tropical diseases · 2025Article
- The prevalence of hepatitis B virus, human T-lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa.Vox sanguinis · 2024Article
- HTLV-1 and blood donation.British journal of haematology · 2024Article
- Epidemiological Evidence of Nosocomial and Zoonotic Transmission of Human T-Cell Leukemia Virus-1 in a Large Survey in a Rural Population of Central Africa.The Journal of infectious diseases · 2023Article
- Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world's largest endemic area.Frontiers in immunology · 2023Review
- Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.Clinical microbiology reviews · 2022Review
- Epidemiology of Adult T-Cell Leukaemia/Lymphoma in South Africa over a 10-Year Period.Journal of cancer epidemiology · 2022Article
- Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of the Implementation of Public Health Policies on HTLV-1 in Brazil.Frontiers in medicine · 2022Article
- Human T-Lymphotropic virus type 1 and human immunodeficiency virus co-infection in rural Gabon.PloS one · 2022Article
- Human T-cell leukemia virus type 1 infection among Japanese immigrants and their descendants living in Southeast Brazil: A call for preventive and control responses.PLoS neglected tropical diseases · 2021Article
- Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains.Emerging microbes & infections · 2020Article
- Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes.Retrovirology · 2019Review
- Health economic implications of testing blood donors in South Africa for HTLV 1 & 2 infection.Vox sanguinis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
BACKGROUND AND
objectivesDonated blood is not currently screened for human T-cell lymphotropic virus (HTLV) in South Africa. Several small studies have detected HTLV-1 in South Africa, but prevalence by geographic region or population group is unavailable. MATERIALS AND
methodsWe performed a large seroprevalence study of South African blood donors during 3 months in 2013. All geographic regions except the Western Cape were included, and Black and Coloured (local term for mixed race) donors were oversampled. Identity-unlinked plasma samples were screened with the Abbott Prism HTLV-1/2 assay, and repeatedly reactive samples were tested by the Inno-LIA HTLV-1/2 Score confirmatory assay. Odds ratios were calculated with multivariable logistic regression.
resultsOf 46 752 donors tested, 133 (0·28%) were initially reactive, 111 (0·24%) repeatedly reactive and 57 (0·12%) confirmed positive for HTLV-1; none were HTLV-2 positive. Prevalence was 0·062% weighted to annual blood donations but highly concentrated in the Black population group (OR = 20·24 CI: 2·77-147·88); higher in females than males (OR = 1·81 CI: 1·06-3·08); and in donors aged >50 years compared to ages 16-19 (OR = 6·4 CI: 2·95-13·86). After controlling for age, sex and population group, there was no difference in prevalence between new and repeat blood donors or among geographic regions within South Africa.
conclusionsWe conclude that HTLV-1 infection is widespread among the Black population of South Africa and its epidemiology is similar to other endemic areas. Because South Africa is increasing its recruitment of Black blood donors, the implications for blood screening require further consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.